In the last years, the research team of Ângela Sousa has been focused on the development of biotechnological strategies with therapeutic potential for cervical cancer treatment. The development of this disease is strongly associated with infection by Human Papillomavirus (HPV), being the latter responsible for the production of E6 and E7 oncoproteins. These proteins have the ability of interfering with cellular regulatory mechanisms fueled by tumor suppressor proteins, such as p53 and pRB proteins.